Chonluten, also referred to as tripeptide T-34, is a synthetic regulatory tripeptide investigated exclusively in laboratory research for its association with transcriptional regulation of genes involved in oxidative-stress signaling and inflammatory-response pathways. Published preclinical studies describe Chonluten-associated modulation of gene-expression profiles in tissue-specific experimental models, including respiratory and gastrointestinal tissues, under controlled in-vitro and in-vivo animal conditions.

Due to its short amino-acid sequence, Chonluten is frequently discussed in the context of low-molecular-weight peptide regulators used as experimental tools to study epigenetic control mechanisms, transcription-factor signaling, and tissue-specific gene-expression responses in aging and stress-adaptation models.

Molecular Formula: C₁₁H₁₇N₃O₈
Molecular Weight: 319.27 g/mol
PubChem CID: 194641
CAS No: 75007-24-8
Alternative Names: T-34 tripeptide, EDG

Source: PubChem

Experimental research on short regulatory peptides, including di-, tri-, and tetrapeptides, demonstrates that these molecules can influence lifespan-associated biomarkers, tumor-development parameters, and transcriptional stability in animal models. These effects are interpreted through peptide-mediated regulation of gene expression, chromatin accessibility, and apoptosis-associated signaling networks in preclinical systems.

Multiple studies indicate that short peptides can influence gene expression through several regulatory layers, including epigenetic mechanisms such as DNA methylation. Computational modeling and in-vitro binding assays suggest that certain short peptides may traverse cellular and nuclear membranes and interact directly with DNA regulatory regions, including promoters and suppressor elements, thereby influencing transcriptional activity.

Research programs associated with the St. Petersburg Institute of Bioregulation and Gerontology have contributed extensively to this field. Within these experimental frameworks, Chonluten has been examined as one of multiple peptide regulators used to investigate peptide–DNA interactions and downstream transcriptional control in cellular and animal models.

Respiratory Tissue Gene-Expression Models

Preclinical studies report tissue-selective transcriptional responses to Chonluten in respiratory epithelial models. These investigations focus on gene-expression changes affecting mucosal-barrier components, extracellular-matrix regulators, and oxidative-stress-response genes under experimentally induced inflammatory or hypoxic conditions.

Genes evaluated in these models include transcription factors and stress-response regulators such as c-FOS, heat-shock proteins (e.g., HSP70), superoxide dismutase (SOD), cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-α), and related antioxidant-pathway components. These genes are commonly used as molecular readouts of cellular stress adaptation, proliferation signaling, and redox balance in laboratory research.

Inflammation-Associated Signaling Pathways

Within experimental inflammatory models, Chonluten has been evaluated for its association with modulation of transcriptional programs linked to cytokine signaling, oxidative-stress regulation, and epithelial-barrier dynamics. Interpretation of these findings remains limited to controlled laboratory systems and does not imply translational or clinical outcomes.

Gastrointestinal Tissue Models

Additional studies examine Chonluten-associated transcriptional effects in gastrointestinal tissue models, with emphasis on vascular signaling, inflammatory-response genes, and oxidative-stress markers measured in preclinical experimental designs.

Research Summary

Collectively, Chonluten is characterized in the literature as a short peptide regulator of gene expression with tissue-specific transcriptional effects in respiratory and gastrointestinal experimental models. Its research utility lies in mechanistic studies of peptide-mediated transcriptional regulation, epigenetic control, and stress-response signaling in vitro and in animal systems.

The above literature was researched, edited and organized by Dr. E. Logan, M.D. Dr. E. Logan holds a doctorate degree from Case Western Reserve University School of Medicine and a B.S. in molecular biology.

Vladimir Khavinson is a Professor, President of the European region of the International Association of Gerontology and Geriatrics; Member of the Russian and Ukrainian Academies of Medical Sciences; Main gerontologist of the Health Committee of the Government of Saint Petersburg, Russia; Director of the Saint Petersburg Institute of Bioregulation and Gerontology; Vice-president of Gerontological Society of the Russian Academy of Sciences; Head of the Chair of Gerontology and Geriatrics of the North-Western State Medical University, St-Petersburg; Colonel of medical service (USSR, Russia), retired. Vladimir Khavinson is known for the discovery, experimental and clinical studies of new classes of peptide bioregulators as well as for the development of bioregulating peptide therapy. He is engaged in studying of the role of peptides in regulation of the mechanisms of ageing. His main field of actions is design, pre-clinical and clinical studies of new peptide geroprotectors. A 40-year-long investigation resulted in a multitude of methods of application of peptide bioregulators to slow down the process of ageing and increase human life span. Six peptide-based pharmaceuticals and 64 peptide food supplements have been introduced into clinical practice by V. Khavinson. He is an author of 196 patents (Russian and international) as well as of 775 scientific publications. His major achievements are presented in two books: “Peptides and Ageing” (NEL, 2002) and “Gerontological aspects of genome peptide regulation” (Karger AG, 2005). Vladimir Khavinson introduced scientific specialty “Gerontology and Geriatrics” in the Russian Federation on the governmental level. Academic Council headed by V. Khavinson has oversighted over 200 Ph.D. and Doctorate theses from many different countries.

Prof. Vladimir Khavinson is being referenced as one of the leading scientists involved in the research and development of Chonluten. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide. Prof. Vladimir Khavinson is listed in [1] [2] [4] [5] [6] and [7] under the referenced citations.

1. V. K. Khavinson, N. S. Lin’kova, A. V. Dudkov, V. O. Polyakova, and I. M. Kvetnoi, “Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins,” Bull. Exp. Biol. Med., vol. 152, no. 5, pp. 615–618, Mar. 2012, doi: 10.1007/s10517-012-1590-2.
2. V. N. Anisimov and V. K. Khavinson, “Peptide bioregulation of aging: results and prospects,” Biogerontology, vol. 11, no. 2, pp. 139–149, Apr. 2010, doi: 10.1007/s10522-009-9249-8.
3. M. A. Voicekhovskaya, N. I. Chalisova, E. A. Kontsevaya, and G. A. Ryzhak, “Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats,” Bull. Exp. Biol. Med., vol. 152, no. 3, pp. 357–359, Jan. 2012, doi: 10.1007/s10517-012-1527-9.
4. V. K. Khavinson, I. G. Popovich, N. S. Linkova, E. S. Mironova, and A. R. Ilina, “Peptide Regulation of Gene Expression: A Systematic Review,” Molecules, vol. 26, no. 22, p. 7053, Nov. 2021, doi: 10.3390/molecules26227053.
5. V. K. Khavinson, N. S. Lin’kova, and S. I. Tarnovskaya, “Short Peptides Regulate Gene Expression,” Bull. Exp. Biol. Med., vol. 162, no. 2, pp. 288–292, Dec. 2016, doi: 10.1007/s10517-016-3596-7.
6. L. I. Fedoreyeva, I. I. Kireev, V. K. Khavinson, and B. F. Vanyushin, “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA,” Biochem. Biokhimii͡a, vol. 76, no. 11, Art. no. 11, Nov. 2011, doi: 10.1134/S0006297911110022.
7. V. Khavinson, N. Linkova, A. Dyatlova, B. Kuznik, and R. Umnov, “Peptides: Prospects for Use in the Treatment of COVID-19,” Molecules, vol. 25, no. 19, p. 4389, Sep. 2020, doi: 10.3390/molecules25194389.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body.  These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease.  Bodily introduction of any kind into humans or animals is strictly forbidden by law.

For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.